For investors, Viking Therapeutics remains important not only as a pipeline company but also as a potential acquisition candidate in a market where large pharma companies want differentiated obesity exposure
The regulator said it conducted an independent assessment of the potential association between GLP-1 RAs and NAION, but found available evidence was conflicting and sought advice from the national advisory committee on medicines on whether the evidence required additional risk-mitigation measures
Justin Klee, co-CEO of Amylyx, told BioSpace that the company is searching for assets with a clear mechanism of action for targeting diseases
GLP-1 agonists for alcohol use disorder represent an emerging area of research interest, though these medications remain unlicensed for this indication in the UK
Elevated levels of utilization, particularly in MA, has been an ongoing trend for the large, national firms, who have seen higher costs in this space for more than a year